Stocktoria
Syndax Pharmaceuticals Inc SNDX
Syndax Pharmaceuticals Inc financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $0 | $139.7M | $1.5M | $1.5M | $1.5M | $2.1M | $1.2M |
| R&D expense | $258.8M | $241.6M | $163.0M | $118.5M | $88.2M | $50.4M | $43.0M | $60.1M | $48.2M | $31.7M |
| SG&A expense | $179.7M | $120.9M | $66.9M | $33.3M | $25.2M | — | — | — | — | — |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M | -$71.4M | -$57.5M | -$75.9M | -$62.0M | -$43.8M |
| Interest expense | — | — | $208,000 | $3.1M | $1.9M | $2.4M | — | — | — | — |
| Income tax | $433,000 | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M | -$73.2M | -$56.0M | -$74.0M | -$60.8M | -$44.5M |
| EPS (diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 | $-1.87 | $-1.84 | — | — | — |
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M | -$71.3M | -$50.6M | -$68.5M | -$47.4M | -$35.2M |
| Free cash flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M | $29.0M | -$71.3M | — | -$68.7M | -$47.5M | -$35.4M |
| Cash & equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $222.0M | $115.2M | $24.6M | $33.8M | $35.2M | $23.8M |
| Inventory | $32.8M | $366,000 | $0 | — | — | — | — | — | — | — |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M | $300.6M | $63.5M | $83.9M | $137.2M | $109.0M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M | $48.4M | $31.9M | $30.9M | $32.9M | $24.9M |
| Shareholders' equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M | $252.2M | $31.6M | $53.0M | $104.3M | $84.1M |
Growth · year-over-year · Revenue CAGR 73.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +627.8% | — | — | -100.0% | +9109.6% | +0.0% | +0.0% | -28.0% | +72.8% | +94.6% |
| Net income growth | — | — | — | -699.1% | — | — | — | — | — | — |
| EPS growth | — | — | — | -634.8% | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | -560.9% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.